undamentalytics Newsletter
Sign in

Marker Therapeutics, Inc. income statement

In fiscal 2025, Marker Therapeutics, Inc. reported revenue of $3.5m, down 46.2% on the year before, operating income of −$12.9m (a -363.5% margin) and net income of −$12.2m, or −$0.79 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMMar 2026
Revenue0001143744
Research and development581319281210131212
General and administrative624101013117444
Operating income−11−148−23−29−39−20−15−11−13−13
Income before tax—————−20−14−11−12—
Income tax00————00−0—
Net income−11−148−21−29−42−30−8−11−12−11
Diluted EPS−$5.80−$77.50−$4.70−$6.10−$5.47−$3.58−$0.94−$1.19−$0.79−$0.63
Diluted shares (average)2m2m5m5m8m8m9m9m15m17m
EBITDA—−148−22−28−37−17————

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DBVT vs MRKRDYAI vs MRKRALGS vs MRKR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Marker Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Marker Therapeutics, Inc.